Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGPU NASDAQ:ICCM NASDAQ:NXL NASDAQ:PETV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGPUPredictive Oncology$5.67-5.0%$3.36$1.03▼$32.10$33.07M3.454.75 million shs236,825 shsICCMIceCure Medical$0.24-4.0%$0.45$0.24▼$1.40$20.30M0.47525,995 shs514,020 shsNXLNexalin Technology$0.35+2.4%$0.41$0.33▼$2.00$7.08M3.56286,952 shs81,971 shsPETVPetVivo$0.80+2.4%$0.76$0.58▼$1.69$28.64M1.2711,282 shs11,792 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGPUPredictive Oncology0.00%+1.02%+32.67%+159.57%+596,999,900.00%ICCMIceCure Medical0.00%-12.59%-25.95%-57.63%-76.30%NXLNexalin Technology0.00%-3.18%-1.71%-33.19%-72.48%PETVPetVivo0.00%0.00%+5.13%-9.24%+26.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGPUPredictive Oncology$5.67-5.0%$3.36$1.03▼$32.10$33.07M3.454.75 million shs236,825 shsICCMIceCure Medical$0.24-4.0%$0.45$0.24▼$1.40$20.30M0.47525,995 shs514,020 shsNXLNexalin Technology$0.35+2.4%$0.41$0.33▼$2.00$7.08M3.56286,952 shs81,971 shsPETVPetVivo$0.80+2.4%$0.76$0.58▼$1.69$28.64M1.2711,282 shs11,792 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGPUPredictive Oncology0.00%+1.02%+32.67%+159.57%+596,999,900.00%ICCMIceCure Medical0.00%-12.59%-25.95%-57.63%-76.30%NXLNexalin Technology0.00%-3.18%-1.71%-33.19%-72.48%PETVPetVivo0.00%0.00%+5.13%-9.24%+26.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGPUPredictive Oncology 1.00SellN/AN/AICCMIceCure Medical 2.25Hold$2.64997.92% UpsideNXLNexalin Technology 1.00SellN/AN/APETVPetVivo 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NXL, AGPU, PETV, and ICCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026ICCMIceCure Medical Alliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/24/2026AGPUPredictive Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026ICCMIceCure Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGPUPredictive Oncology$120K261.77N/AN/A$11.69 per share0.49ICCMIceCure Medical$3.38M5.76N/AN/A$0.12 per share2.00NXLNexalin Technology$300K24.17N/AN/A$0.20 per share1.76PETVPetVivo$1.05M27.38N/AN/A($0.03) per share-26.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGPUPredictive Oncology-$233.10M-$12.62N/AN/AN/A-185,476.72%N/A-970.41%N/AICCMIceCure Medical-$15.06M-$0.24N/AN/AN/A-445.61%-221.04%-118.89%5/14/2026 (Estimated)NXLNexalin Technology-$8.22M-$0.51N/AN/AN/A-2,722.19%-195.69%-171.05%6/3/2026 (Estimated)PETVPetVivo-$10.95M-$0.38N/AN/AN/A-902.82%-4,813.07%-281.78%6/25/2026 (Estimated)Latest NXL, AGPU, PETV, and ICCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/ANXLNexalin Technology-$0.10N/AN/AN/A$0.02 millionN/A5/14/2026Q1 2026ICCMIceCure Medical-$0.03N/AN/AN/A$1.34 millionN/A5/8/2026Q1 2026NXLNexalin TechnologyN/A-$0.11N/A-$0.11N/A$0.01 million3/31/2026Q4 2025AGPUPredictive OncologyN/A$122.75N/A$122.75N/A$0.01 million3/25/2026Q4 2025NXLNexalin Technology-$0.12-$0.13-$0.01-$0.13$0.08 million$0.17 million3/17/2026Q4 2025ICCMIceCure Medical-$0.04-$0.06-$0.02-$0.0620$1.30 million$1.28 million2/15/2026Q4 2025ICCMIceCure MedicalN/A$0.06N/A$0.06N/A$1.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGPUPredictive OncologyN/AN/AN/AN/AN/AICCMIceCure MedicalN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGPUPredictive OncologyN/A10.0210.02ICCMIceCure MedicalN/A2.612.07NXLNexalin TechnologyN/A4.854.70PETVPetVivo0.020.420.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGPUPredictive Oncology9.04%ICCMIceCure Medical0.62%NXLNexalin Technology0.65%PETVPetVivo24.55%Insider OwnershipCompanyInsider OwnershipAGPUPredictive Oncology1.21%ICCMIceCure Medical2.44%NXLNexalin Technology25.26%PETVPetVivo10.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGPUPredictive Oncology305.54 million5.47 millionN/AICCMIceCure Medical6081.18 million79.20 millionNot OptionableNXLNexalin Technology320.58 million15.38 millionNot OptionablePETVPetVivo2035.85 million19.06 millionNot OptionableNXL, AGPU, PETV, and ICCM HeadlinesRecent News About These CompaniesPeer To Peer Network: PTOP's AI Partner Tier 1 AI, Signs Contract With OTCQX:PETV as Enterprise ClientApril 29, 2026 | finanznachrichten.dePTOP’s AI Partner Tier 1 AI, Signs Contract With OTCQX:PETV as Enterprise ClientApril 29, 2026 | usatoday.comPetVivo Holdings, Inc. to Present at the Market Movers Investor SummitApril 21, 2026 | newsfilecorp.comNPETVIVO HOLDINGS, INC. TO EXHIBIT AT THE ACVSMR SYMPOSIUM IN LEXINGTON, KENTUCKYMarch 19, 2026 | cincinnati.comCPetVivo Holdings: Balancing Ambitious Growth with Financial RealityFebruary 23, 2026 | newscase.comNPetVivo Holdings Inc (PETV) Q3 2026 Earnings Call Highlights: Strategic Partnerships and AI ...February 19, 2026 | finance.yahoo.comPetVivo Holdings, Inc.: PetVivo Reports Results for Third Quarter and First Nine Months of Fiscal 2026February 18, 2026 | finanznachrichten.dePetVivo Holdings, Inc. (OTC:PETV) Q3 2026 earnings call transcriptFebruary 18, 2026 | msn.comPetVivo Reports Results for Third Quarter and First Nine Months of Fiscal 2026February 18, 2026 | finance.yahoo.comPetVivo Holdings, Inc. (PETV) Q3 2026 Earnings Call TranscriptFebruary 17, 2026 | seekingalpha.comPETVIVO HOLDINGS, INC. TO EXHIBIT AT THE 2026 OCALA EQUINE CONFERENCE IN OCALA, FLORIDAFebruary 15, 2026 | azcentral.comAPetVivo Issues Correction and Replacement Press Release; Sets Fiscal Third Quarter 2026 Conference Call for Tuesday, February 17, 2026 at 5:00 p.m. ETFebruary 10, 2026 | globenewswire.comPetVivo Sets Fiscal Third Quarter 2026 Conference Call for Monday, February 16, 2026 at 5:00 p.m. ETFebruary 9, 2026 | globenewswire.comPetVivo Holdings, Inc. Announces Health Canada Acknowledgement of Spryng® as a Veterinary Medical DeviceJanuary 21, 2026 | finance.yahoo.comNew To The Street T.V. Commercials Break Digital RecordsJanuary 3, 2026 | newsobserver.comNPetVivo Holdings, Inc. Presenting at the 3rd Annual DealFlow Discovery ConferenceDecember 23, 2025 | accessnewswire.comAPetVivo.ai Breaks the Mold: Launches Video Explainer Because "Nobody Reads Tech Press Releases Anymore"December 16, 2025 | globenewswire.comPetVivo launches AI platform reducing vet client acquisition costsNovember 25, 2025 | msn.comPetVivo Launches AI Platform Reducing Veterinary Client Acquisition Costs by 50-89%November 25, 2025 | markets.businessinsider.comUPDATED: PetVivo AI, Inc. Launches AI Platform Reducing Veterinary Client Acquisition Costs by 50-90%November 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNXL, AGPU, PETV, and ICCM Company DescriptionsPredictive Oncology NASDAQ:AGPU$5.67 -0.30 (-5.03%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$5.56 -0.11 (-2.01%) As of 05/8/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.IceCure Medical NASDAQ:ICCM$0.24 -0.01 (-4.00%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.24 +0.00 (+1.25%) As of 05/8/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.Nexalin Technology NASDAQ:NXL$0.35 +0.01 (+2.44%) Closing price 05/8/2026 03:59 PM EasternExtended Trading$0.34 -0.01 (-2.95%) As of 05/8/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.PetVivo NASDAQ:PETV$0.80 +0.02 (+2.37%) As of 05/8/2026 03:40 PM EasternPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
